Company news
Cosciens Biopharma Inc. (TSX:CSCI) news
Cosciens Biopharma Inc. news releases on 6ix. Latest, Jun 2, 2014: Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC…
Press releases — page 3
Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial in Endometrial Cancer
June 2, 2014
Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO
May 22, 2014
Aeterna Zentaris Announces Board of Directors Leadership Change and Election of Directors at Annual Meeting of Shareholders
May 12, 2014
Aeterna Zentaris Announces At the Market Issuance Program
May 9, 2014
Aeterna Zentaris Reports First Quarter 2014 Financial and Operating Results
May 8, 2014
Aeterna Zentaris Selects Charleston, S.C. as New Location for its North American Business and Global Commercial Operations
May 5, 2014
Aeterna Zentaris to Announce First Quarter 2014 Financial and Operating Results on May 8, 2014 and Hold Annual Shareholders Meeting on May 9, 2014
April 30, 2014
Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors
April 9, 2014
Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego
April 1, 2014
Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for "At-the-Market" Common Share Issuance Programs
March 28, 2014
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results
March 20, 2014
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014
March 12, 2014
Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer
February 4, 2014
Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH
February 3, 2014
Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants
January 14, 2014
Aeterna Zentaris Announces Pricing of US$13.2 Million Public Offering of Common Shares and Warrants
January 9, 2014
Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA
January 6, 2014
Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer
January 3, 2014
Aeterna Zentaris Announces Closing of US$15.1 Million Public Offering of Common Shares and Warrants
November 25, 2013
Aeterna Zentaris Announces Pricing of US$15.1 Million Public Offering of Common Shares and Warrants
November 20, 2013
Aeterna Zentaris Reports Third Quarter 2013 Financial and Operating Results
November 5, 2013
Aeterna Zentaris Appoints Chief Commercial Officer, Reaffirming New Company Vision
November 1, 2013
Aeterna Zentaris to Announce Third Quarter 2013 Financial and Operating Results on November 5, 2013
October 29, 2013
Aeterna Zentaris Completes Successful Transfer of Cetrotide® Manufacturing Rights to Merck KGaA
October 1, 2013
Aeterna Zentaris Announces Listing Transfer to NASDAQ Capital Market
August 28, 2013
Aeterna Zentaris Reports Second Quarter 2013 Financial and Operating Results
August 8, 2013
Aeterna Zentaris to Present at Upcoming Canaccord Genuity Global Growth Conference in Boston
August 7, 2013
Aeterna Zentaris to Announce Second Quarter 2013 Financial and Operating Results on August 8, 2013
August 1, 2013
Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin (AEZS-108)
July 31, 2013
Aeterna Zentaris Completes $7.8 Million Registered Direct Offering
July 30, 2013
Aeterna Zentaris to Raise US$7.8 Million in Registered Direct Offering
July 25, 2013
Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO
June 3, 2013
Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting
May 23, 2013
Aeterna Zentaris Announces "At-the-Market" Issuance Program
May 21, 2013
Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders
May 8, 2013
Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results
May 7, 2013
Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013
May 1, 2013
Aeterna Zentaris Newly Appointed CEO, David A. Dodd, to Host Introductory Analyst and Investor Conference Call on Thursday, April 25, 2013
April 23, 2013
Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to Cetrotide® to Merck KGaA
April 17, 2013
David A. Dodd Appointed President & Chief Executive Officer of Aeterna Zentaris Inc.
April 15, 2013
Aeterna Zentaris Presents Encouraging Updated Data on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at AACR Meeting
April 10, 2013
Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual Meeting
April 3, 2013
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results
March 21, 2013
Aeterna Zentaris to Present at Upcoming Roth 25th Annual OC Growth Stock Conference
March 13, 2013
Aeterna Zentaris to Announce Fourth Quarter and Full Year 2012 Financial and Operating Results on March 21, 2013
March 12, 2013
IIROC Trade Resumption - AEZ (all issues)
March 11, 2013
Aeterna Zentaris: First Patient Treated for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer
February 20, 2013
Aeterna Zentaris Granted Special Protocol Assessment by the FDA for Phase 3 Registration Trial in Endometrial Cancer with AEZS-108
December 28, 2012
Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients
December 11, 2012
Aeterna Zentaris to Present at Oppenheimer 23rd Annual Healthcare Conference in New York
December 4, 2012